Variations of the hepatic SUV in relation to the body mass index in whole body PET-CT studies;Variaciones del SUV hepático con relación al índice de masa corporal en estudios PET/TC de cuerpo entero

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 32, Issue 1, 2013, Pages 26-32

  Batalles S M ^a   Villavicencio, R L ^a   Quaranta, A ^a   Burgos, L ^a   Trezzo, S ^a   Staffieri, R ^a   Pezzotto, S M ^a  

^a Instituto de Diagnóstico Médico Oroño   (Argentina)

Author keywords

Body mass index; Liver Standard Uptake Value; Positron Emission Tomography Scan Scans

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; ARTICLE; BODY MASS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; OBESITY; PREDICTION; RETROSPECTIVE STUDY; WHOLE BODY PET;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84871602832     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2012.02.003     Document Type: Article

References (28)

1. Warburg O., Wind F., Neglers E. On the metabolism of tumors in the body. Metabolism of tumors. 1930, 254-270. Constable, Londres. O. Warburg (Ed.).
2. Kostakoglu L., Agress H., Goldsmith S.J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003, 23:315-340.
3. Kamimura K., Nagamachi S., Wakamatsu H., Higashi R., Ogita M., Ueno S., et al. Associations between liver 18F fluoro-2-deoxy-D-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome. Ann Nucl Med 2010, 24:157-161.
4. Gámez Cenzano C., Cabrera Villegas A., Sopena Monforte R., García Velloso M.J. La tomografía por emisión de positrones (PET) en Oncología (Parte I). Rev Esp Med Nucl 2002, 21:41-60.
5. Gil Martínez E.M., Mohedano Ferrer B., Ramírez López M.A., González Cabezas P., Durán Barquero C., Moya García F. Captación fisiológica y no maligna de [18]FDG en estudio PET de cuerpo completo. Alasbimn Journal 2007, 9. Article N° AJ35-4.
6. Tomografía de positrones (PET) de cuerpo entero con fluordesoxiglucosa-18F - Whole body positron emission tomography (PET) with 18F-fluordesoxyglucose. Rev Esp Med Nucl 2002, 21:128-130. Grupo PET de la SEMM.
7. Baena Cañada J.M. Manejando la respuesta terapéutica del tumor con PET. Rev Esp Med Nucl 2010, 29:273-274.
8. Kumar R., Xiu Y., Yu J.Q., Takalkar A., El-Haddad G., Potenta S., et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004, 45:2058-2062.
9. Tournoy K.G., Madddens S., Gosselin R., Van Maele G., Van Meerbeeck J.P., Kelles A. Integrated FDGPET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax 2007, 62:696-701.
10. Yoshida Y., Kurokawa T., Sawamura Y., Shinagawa A., Tsujikawa T., Okazawa H., et al. Comparison of 18F-FDG PET and MRI in assessment of uterine smooth muscle tumors. J Nucl Med 2008, 49:708-712.
11. Walter M.A., Melzer R.A., Schindler C., Müller-Brand J., Tyndall A., Nitzsche E.U. The value of [18F] FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005, 32:674-681.
12. Louis E., Ancion G., Colard A., Spote V., Belaiche J., Hustinx R. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med 2007, 48:1053-1059.
13. Inoue K., Goto R., Okada K., Kinomura S., Fukuda H. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Ann Nucl Med 2009, 23:643-649.
14. Abele J., Fung C. Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology 2010, 254:917-924.
15. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
16. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 2005, 143:722-728.
17. Kim Y.W., Kim J.Y., Jang S.J., Chung H.W., Jang K-S., Paik S.S., et al. F-18 FDG uptake in focal fatty infiltration of liver mimicking hepatic malignancy on PET/CT images. Clin Nucl Med 2011, 36:1146-1148.
18. 18F-FDG en el seguimiento de pacientes con linfoma: detección de recidivas asintomáticas. Rev Esp Med Nucl 2012, 31:22-27.
19. Lin CY, Lin WY, Lin CC, Shih CM, Jeng LB, Kao CH. The negative impact of fatty liver on máximum standard uptake value of liver on FGD PET. Clin Imaging. 2011;35:437-41.
20. National Heart, Lung, and Blood Institute. National Institutes of Health. North American Association for the study of obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. [consultado 14 Jul 2011]. Disponible en: http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf.
21. WHO Technical Report Series 894. World Health Organization. " Obesity: preventing and managing the global epidemic" Ginebra: World Health Organization, 2000 [consultado 13 Nov 2011]. Disponible en: http://www.bvsde.paho.org/bvsacd/cd66/obeprev/indice.pdf.
22. Tan L.T., Ong K.L. Semi-quantitative measurements of normal organs with variable metabolic activity on FDG PET imaging. Ann Acad Med Singapore 2004, 33:183-185.
23. El-Haddad G., Alavi A., Mavi A., Bural G., Zhuang H. Normal variants in [18F]- fluorodeoxyglucose PET imaging. Radiol Clin N Am 2004, 42:1063-1081.
24. Chun-Yi L., Hueisch-Jy D., Cheng-Chieh L., Cheng-Chieh Ch, Shung-Shung S., Chia-Hung K. Impact of age on FDG uptake in the liver on PET scan. Clin Imaging 2010, 34:348-350.
25. Thie J.A., Hubner K.F., Isidoro F.P., Smith G.T. A weight index for the standardized uptake value in 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol 2007, 9:91-98.
26. Qazi F., Oliver D., Nguyen N., Osman M. Fatty liver: impact on metabolic activity as detected with 18F FDG-PET/CT. J Nucl Med 2008, 49:263P.
27. Kubota K., Watanabe H., Murata Y., Yukihiro M., Ito K., Morooka M., et al. Effects of blood glucose level on FDG uptake by liver: a FDG-PET/CT study. Nucl Med Biol 2011, 38:347-351.
28. Paquet N., Albert A., Foidart J., Hustinx R. Within-patient variability of 18F-FDG: Standardized Uptake Values in Normal Tissues. J Nucl Med 2004, 45:784-788.